Search

Non-invasive prenatal testing (NIPT) is a genomic technology used to predict the chance of a foetus having a genetic condition. Despite the immediacy of this technology's integration into clinical practice, there is a dearth of evidence outlining how both patients and professionals experience NIPT on the ground. In this article, we draw upon our collective empirical research—specifically on earlier screening technologies (BKR), Down syndrome screening (GT), genetic screening/testing (JL) and NIPT (HS)—to outline the most pressing and often controversial issues which, we argue, remain unresolved and vital to consider regarding NIPT. We begin with a brief introduction to NIPT as a prenatal technology and the bodies of literature which unpack its 'social life'. In what follows, BKR discusses NIPT within the context of her research on 'the tentative pregnancy' and diagnostic testing in the USA. In the following sections, GT, HS and JL identify different, but related, concerns with respect to NIPT, particularly around routinisation, commercialisation, choice, abortion, and configurations of disability and 'normalcy'. [ABSTRACT FROM AUTHOR]

Gestational trophoblastic disease is a group of placental disorders that hydatidiform mole is the most common form. It is considered a benign condition that may develop into other malignant forms, referred indistinctly as gestational trophoblastic neoplasia (GTN). Patients with trophoblastic neoplasia are classified by the presence of risk factors according to the International Federation of Gynecology and Obstetrics' (FIGO) prognostic score having low-risk disease that receiving a single chemotherapy agent and high-risk disease that receiving combination chemotherapy. Adverse effect was reported that influence the outcome of subsequent pregnancy after chemotherapy. A case report of outcome of subsequent pregnancy after three times got etoposide+methotrexate+actinomycin-D alternating with cyclophosphamide+vincristine (EMA/CO) chemotherapy for high risk gestational trophpblastic neoplasia and nine months after that she conceived. During her pregnancy non-invasive prenatal testing (NIPT) was did to screen whether she had fetal abeuploidy and the result was low risk. She delivered at term, born healthy baby. In conclusion, the recommendation interval for subsequent pregnancy after chemotherapy for gestational thropoblastic neoplasm is recomended at least 6 months or more after completion chemotherapy. NIPT is used as a screening method to detect fetal chromosomal aneuploidies. Keyword: gestational trophoblastic neoplasia (GTN), chemotherapy, Non-invasive prenatal testing (NIPT), subsequent pregnancy [ABSTRACT FROM AUTHOR]